Dr. Douglas Faller

Dr. Faller holds an M.D. from Harvard University, and a Ph.D. in Cancer Molecular Biology and a B.S. in Biochemistry from the Massachusetts Institute of Technology. He has been a professor at Harvard Medical School/Dana-Farber Cancer Institute/Brigham and Women’s Hospital and Boston Children’s Hospital. He held the Grunebaum Chair for Cancer Research at Boston University and was professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine. He founded the Cancer Center at Boston University, and served as the Director of the Center, and also as Vice-Chairman of the Department of Medicine. He is the scientific founder of multiple biotech companies. He has served as CMO and CSO of a number of companies, including, most recently, at Viracta Therapeutics. He has served as Executive Medical Director and Global Clinical Leader at Takeda for more than 5 years. Dr Faller has over 30 years of clinical hematology/oncology expertise and broad drug development experience in the design and execution of early to registrational clinical programs across oncology and rare diseases. Before joining Oryzon’s SAB, Dr. Faller was Global Chief Medical Officer at Oryzon.